Braidwell »

Cg Oncology shares owned by Braidwell

Quarter-by-quarter ownership of Cg Oncology (CGON) shares owned by Braidwell from 13F filings

Historical chart of Braidwell investment in Cg Oncology

Tip: Access up to 7 years of quarterly data

All positions including Cg Oncology held by Braidwell consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Cg Oncology by Braidwell

Quarter filed Position value Share count Share price at filing
2024-09-30 $120M 3.2M 37.73
2024-06-30 $105M 3.3M 31.57
2024-03-31 $50M 1.1M 43.90

More positions owned by Braidwell

Guardant Health Note11/1 (Principal)
Bridgebio Pharma Note 2.500% 3/1 (Principal)
Novocure Note11/0 (Principal)
Cg Oncology (CGON)
Nuvasive Note 0.375% 3/1 (Principal)
Xenon Pharmaceuticals (XENE)
Neurocrine Biosciences (NBIX)
Neogenomics Note 0.250% 1/1 (Principal)
Apogee Therapeutics (APGE)
Apellis Pharmaceuticals (APLS)
Ironwood Pharmaceuticals Note 1.500% 6/1 (Principal)
Dexcom Note 0.375% 5/1 (Principal)
Align Technology (ALGN)
Guardant Health (GH)
Insulet Corp Note 0.375% 9/0 (Principal)

View all positions for Braidwell

Top funds holding Cg Oncology

Decheng Capital
TCG Crossover Management
BlackRock
Braidwell
Vanguard Group
BlackRock
Avidity Partners Management
Henderson Group
RA Capital Management
Franklin Resources
Geode Capital Management
Alliancebernstein
BVF
State Street Corporation
Cormorant Asset Management

View all funds holding Cg Oncology